Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Emily Bodnar maintains IO Biotech (NASDAQ:IOBT) with a Buy and raises the price target from ...
HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:IOBT) with a Buy and maintains $8 price target.
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) ...
As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as ...
IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating therapeutic cancer vac...
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quart...
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...
